Literature DB >> 7505039

Immunohistochemical distribution and quantification of crystal matrix protein.

A M Stapleton1, A E Seymour, J S Brennan, I R Doyle, V R Marshall, R L Ryall.   

Abstract

The aim of this study was to determine the immunohistochemical distribution and quantification of crystal matrix protein (CMP). CMP, a 31 kDa glycoprotein, is the principal macromolecule found in calcium oxalate crystals generated in human urine, and is a potent inhibitor of crystal aggregation. A polyclonal rabbit anti-human CMP antibody was used to examine renal tissue by immunohistochemical techniques and light microscopy (N = 45). Twenty-five other human organs were similarly assessed. Quantification was performed using a visual analogue scale. CMP was visible as cytoplasmic staining in the epithelial cells of the TALH and the distal convoluted tubule including the macula densa in a subgroup of nephrons. CMP was not identified elsewhere in the urinary tract or in the extrarenal organs examined. Despite a trend indicating that the kidneys of normal men had more CMP than those of normal women, the difference failed to reach significance (P = 0.11). There was, however, more CMP in the stone formers group compared with either normal men (P < 0.01) or normal women (P < 0.01). This protein may be an important determinant of calcium oxalate kidney stone disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505039     DOI: 10.1038/ki.1993.316

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Protective effect of dietary polyphenol caffeic acid on ethylene glycol-induced kidney stones in rats.

Authors:  Fauzia Yasir; Atia-Tul- Wahab; M Iqbal Choudhary
Journal:  Urolithiasis       Date:  2017-06-14       Impact factor: 3.436

2.  Calcium Oxalate Stone Agglomeration Inhibition [tm] Reflects Renal Stone-Forming Activity.

Authors:  J S Lindberg; F E Cole; W Romani; F E Husserl; H A Fuselier; D J Kok; D T Erwin
Journal:  Ochsner J       Date:  2000-04

Review 3.  Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation.

Authors:  R L Ryall
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

4.  In vitro crystallisation systems for the study of urinary stone formation.

Authors:  W Achilles
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Glycosaminoglycans, proteins, and stone formation: adult themes and child's play.

Authors:  R L Ryall
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

6.  Protein Z and protein Z-dependent protease inhibitor and renal tubules.

Authors:  G J Broze; Y Tu
Journal:  Thromb Haemost       Date:  2009-12-18       Impact factor: 5.249

Review 7.  Animal models of kidney stone formation: an analysis.

Authors:  S R Khan
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

8.  Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.

Authors:  Naim M Maalouf; Alicia H Sato; Brian J Welch; Barbara V Howard; Barbara B Cochrane; Khashayar Sakhaee; John A Robbins
Journal:  Arch Intern Med       Date:  2010-10-11

9.  Simple, sensitive and accurate method for the quantification of prothrombin mRNA by using competitive PCR.

Authors:  P K Grover; A M Stapleton; K Miyazawa; R L Ryall
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

10.  Calcium oxalate crystal matrix extract: the most potent macromolecular inhibitor of crystal growth and aggregation yet tested in undiluted human urine in vitro.

Authors:  I R Doyle; V R Marshall; C J Dawson; R L Ryall
Journal:  Urol Res       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.